SPOTLIGHT: Ranbaxy cuts US staff with drop in profits

Hit with a 47 percent decline in second-quarter profits, India's Ranbaxy has cut staff in the US and slashed its marketing budget. Ranbaxy's chief told the Economic Times that the company plans to reverse its fortunes in part through the introduction of new products in the US market. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.